We can make available to you background information about Evista, and provide referrals to expert scientists and physicians who can offer more information about this issue. They all found that raloxifene is safe for postmenopausal women and not associated with ovarian cancer. In fact, studies are now planned to explore whether raloxifene may even prevent breast cancer. In clinical studies of nearly 13,000 women, raloxifene was shown to help preserve a woman's bones and prevent osteoporosis. Raloxifene also has demonstrated a positive effect on cholesterol levels and is safe in the breast and uterus.
Studies are ongoing to explore raloxifene's potential in preventing heart disease and breast cancer.
Today, women are living a full one-third of their lives past menopause. It is important for these women to have new options to protect their postmenopausal health. Keeping a true scientific advancement like raloxifene from potential patients through unfounded scare tactics does a disservice to all women.